ArticleClinical and experimental immunology2023

Antinuclear antibody (ANA) status predicts immune-related adverse events in liver cancer patients undergoing anti-PD-1 therapy.

Shu-Jung Hsu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.